Financial Data and Key Metrics Changes - The company reported total revenues of $239.7 million for the second quarter, a 14.7% increase compared to $209 million in the same quarter of fiscal year 2025 [21] - Adjusted EBITDA for the quarter was $22.2 million, compared to $5.9 million in the second quarter of fiscal year 2025, achieving an adjusted EBITDA margin of 9.2% [26][27] - Net income was $11.8 million for the quarter, a significant improvement from a net loss of $13.5 million in the second quarter of fiscal year 2025 [26] Business Line Data and Key Metrics Changes - The company served approximately 8,010 participants across 20 centers, representing a 7.1% growth compared to the second quarter of fiscal year 2025 [19] - Member months totaled 23,960 in the second quarter, an increase of approximately 7.9% compared to the same quarter of fiscal year 2025 [20] Market Data and Key Metrics Changes - The company experienced a slightly more favorable blended rate environment for Medicaid this fiscal year compared to initial assumptions [10] - The Medicare Advantage rates for calendar year 2027 were discussed, indicating that changes in Medicare policy affect the company's operations [11] Company Strategy and Development Direction - The company is focused on strengthening revenue integrity, particularly around Medicaid eligibility and redeterminations, which has shown positive results [8] - There is a commitment to improving participant experience through systematic feedback and continuous improvement initiatives [13] - The governance structure has evolved to support the next phase of execution, with key leadership changes aimed at enhancing oversight [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's operational improvements and raised full-year fiscal 2026 guidance, expecting total revenue between $925 million and $950 million [17][30] - The company acknowledged the inherent variability in its business model but emphasized that the platform is increasingly operating as designed [16] Other Important Information - The company ended the quarter with $83.2 million in cash and cash equivalents and $42.8 million in short-term investments [29] - De novo center losses were reported at $4.7 million for the quarter, primarily related to new centers in Florida [27] Q&A Session Summary Question: Regarding EBITDA progression in the back half of the year - Management noted that the third quarter is typically softer due to seasonal factors and enrollment dynamics, with expectations for a return to normalized growth in Q4 [34][35] Question: Impact of V28 on risk scores - Management discussed the phased-in implementation of the risk adjustment model and its implications for the company's rates, emphasizing that PACE shares similarities with Medicare rate adjustments [39][41] Question: Success in Medicaid redeterminations - Management highlighted improvements in internal processes and collaboration with state-level approvals, leading to better outcomes in reinstating Medicaid coverage [46][48] Question: Patient experience and retention initiatives - Management provided insights into the importance of aligning participant expectations with their experiences, identifying key areas for improvement in the onboarding process and service recovery [57][59]